MYC-induced repression of CDK18, as well as ATR inhibition, affects ATR activity, and increases sensitivity to PARPi, thus representing a promising therapy for glioblastoma and, potentially, other PARPi-refractory tumors. Here, ATR is linked to glioblastoma.